![Jennifer Hamilton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Jennifer Hamilton
Former positions of Jennifer Hamilton
Companies | Position | Start | End |
---|---|---|---|
Trillium Therapeutics, Inc. /Old/
![]() Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Director/Board Member | 14/12/2010 | 06/06/2014 |
Phase4 Partners Ltd.
![]() Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Corporate Officer/Principal | 01/01/2001 | 01/01/2010 |
United Neighborhood Health Services, Inc.
![]() United Neighborhood Health Services, Inc. Hospital/Nursing ManagementHealth Services United Neighborhood Health Services, Inc. provides health care services. It offers homeless services, mobile clinic, dental, diabetes and other medical care services. The company was founded in 1976 and is headquartered in Nashville, TN. | Director/Board Member | 27/09/2011 | - |
President | 27/09/2011 | - | |
Rothschild Asset Management Ltd. | Corporate Officer/Principal | - | - |
Training of Jennifer Hamilton
University of British Columbia | Doctorate Degree |
Statistics
International
United Kingdom | 3 |
Canada | 3 |
United States | 2 |
Operational
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Doctorate Degree | 1 |
Sectoral
Finance | 2 |
Miscellaneous | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
Phase4 Partners Ltd.
![]() Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Finance |
Rothschild Asset Management Ltd. | Miscellaneous |
Trillium Therapeutics, Inc. /Old/
![]() Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
United Neighborhood Health Services, Inc.
![]() United Neighborhood Health Services, Inc. Hospital/Nursing ManagementHealth Services United Neighborhood Health Services, Inc. provides health care services. It offers homeless services, mobile clinic, dental, diabetes and other medical care services. The company was founded in 1976 and is headquartered in Nashville, TN. | Health Services |
- Stock Market
- Insiders
- Jennifer Hamilton
- Experience